Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Loss of 5-hydroxymethylcytosine and ten-eleven translocation 2 protein expression in malignant melanoma.

Gambichler T, Sand M, Skrygan M.

Melanoma Res. 2013 Jun;23(3):218-20. doi: 10.1097/CMR.0b013e32835f9bd4.

PMID:
23458759
2.

Loss of 5-hydroxymethylcytosine and TET2 in oral squamous cell carcinoma.

Jäwert F, Hasséus B, Kjeller G, Magnusson B, Sand L, Larsson L.

Anticancer Res. 2013 Oct;33(10):4325-8.

PMID:
24122999
3.

Versican overexpression in cutaneous malignant melanoma.

Gambichler T, Kreuter A, Grothe S, Altmeyer P, Brockmeyer NH, Rotterdam S.

Eur J Med Res. 2008 Nov 24;13(11):500-4.

PMID:
19073385
4.

Protein expression of carcinoembryonic antigen cell adhesion molecules in benign and malignant melanocytic skin lesions.

Gambichler T, Grothe S, Rotterdam S, Altmeyer P, Kreuter A.

Am J Clin Pathol. 2009 Jun;131(6):782-7. doi: 10.1309/AJCP24KXJVBZXENS.

PMID:
19461083
5.

IMP-3 is a novel progression marker in malignant melanoma.

Pryor JG, Bourne PA, Yang Q, Spaulding BO, Scott GA, Xu H.

Mod Pathol. 2008 Apr;21(4):431-7. doi: 10.1038/modpathol.3801016. Epub 2008 Jan 18.

6.

bcl-2 protein expression in melanocytic neoplasms of the skin.

Ramsay JA, From L, Kahn HJ.

Mod Pathol. 1995 Feb;8(2):150-4.

PMID:
7777475
7.

Expression of the embryonic morphogen Nodal in cutaneous melanocytic lesions.

Yu L, Harms PW, Pouryazdanparast P, Kim DS, Ma L, Fullen DR.

Mod Pathol. 2010 Sep;23(9):1209-14. doi: 10.1038/modpathol.2010.101. Epub 2010 May 21.

8.

Immunohistochemical analysis of Bcl-2 protein regulation in cutaneous melanoma.

Tron VA, Krajewski S, Klein-Parker H, Li G, Ho VC, Reed JC.

Am J Pathol. 1995 Mar;146(3):643-50.

9.

Loss of 5-hydroxymethylcytosine correlates with increasing morphologic dysplasia in melanocytic tumors.

Larson AR, Dresser KA, Zhan Q, Lezcano C, Woda BA, Yosufi B, Thompson JF, Scolyer RA, Mihm MC Jr, Shi YG, Murphy GF, Lian CG.

Mod Pathol. 2014 Jul;27(7):936-44. doi: 10.1038/modpathol.2013.224. Epub 2014 Jan 3.

10.

TET2 gene expression and 5-hydroxymethylcytosine level in multiple sclerosis peripheral blood cells.

Calabrese R, Valentini E, Ciccarone F, Guastafierro T, Bacalini MG, Ricigliano VA, Zampieri M, Annibali V, Mechelli R, Franceschi C, Salvetti M, Caiafa P.

Biochim Biophys Acta. 2014 Jul;1842(7):1130-6. doi: 10.1016/j.bbadis.2014.04.010. Epub 2014 Apr 13.

11.

Expression of the ets-1 proto-oncogene in melanocytic lesions.

Keehn CA, Smoller BR, Morgan MB.

Mod Pathol. 2003 Aug;16(8):772-7.

12.

Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation.

Yang H, Liu Y, Bai F, Zhang JY, Ma SH, Liu J, Xu ZD, Zhu HG, Ling ZQ, Ye D, Guan KL, Xiong Y.

Oncogene. 2013 Jan 31;32(5):663-9. doi: 10.1038/onc.2012.67. Epub 2012 Mar 5.

14.

Dynamics of ten-eleven translocation hydroxylase family proteins and 5-hydroxymethylcytosine in oligodendrocyte differentiation.

Zhao X, Dai J, Ma Y, Mi Y, Cui D, Ju G, Macklin WB, Jin W.

Glia. 2014 Jun;62(6):914-26. doi: 10.1002/glia.22649. Epub 2014 Feb 25.

PMID:
24615693
15.

Cytoplasmic BRMS1 expression in malignant melanoma is associated with increased disease-free survival.

Slipicevic A, Holm R, Emilsen E, Ree Rosnes AK, Welch DR, Mælandsmo GM, Flørenes VA.

BMC Cancer. 2012 Feb 22;12:73. doi: 10.1186/1471-2407-12-73.

16.

Advances in DNA methylation: 5-hydroxymethylcytosine revisited.

Dahl C, Grønbæk K, Guldberg P.

Clin Chim Acta. 2011 May 12;412(11-12):831-6. doi: 10.1016/j.cca.2011.02.013. Epub 2011 Feb 12. Review.

PMID:
21324307
17.

Cdc7 expression in melanomas, Spitz tumors and melanocytic nevi.

Clarke LE, Fountaine TJ, Hennessy J, Bruggeman RD, Clarke JT, Mauger DT, Helm KF.

J Cutan Pathol. 2009 Apr;36(4):433-8. doi: 10.1111/j.1600-0560.2008.01077.x.

PMID:
19278428
18.

Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression.

Montone KT, van Belle P, Elenitsas R, Elder DE.

Mod Pathol. 1997 Sep;10(9):939-44.

PMID:
9310959
19.

PUMA expression is significantly reduced in human cutaneous melanomas.

Karst AM, Dai DL, Martinka M, Li G.

Oncogene. 2005 Feb 3;24(6):1111-6.

PMID:
15690057
20.

Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.

Boyd AS, Shakhtour B, Shyr Y.

J Am Acad Dermatol. 2008 May;58(5):750-4. doi: 10.1016/j.jaad.2007.12.026. Epub 2008 Feb 4.

PMID:
18249467

Supplemental Content

Support Center